Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Laboratories Ltd.

http://www.drreddys.com

Latest From Dr. Reddy's Laboratories Ltd.

Five New EU Filings Leave Starting Blocks at EMA

There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.

Europe Review Pathway

Ichnos Capital Raise Key For Glenmark, BEAT Platform A Core Value Driver

All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.

Commercial Financing

‘Clinically Proven’ Claim Leaving RB's Brain Health Supplements In US Class Action Settlement

Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.

Dietary Supplements Legal Issues

H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.

Regulation Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Aurigene Discovery Technologies
    • OctoPlus N.V.
    • Promius Pharma LLC
    • Dr. Reddy's Research and Development B.V.
    • Imperial Credit Private Limited
    • Wockhardt Limited
UsernamePublicRestriction

Register